SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Nos, C.
Right arrow Articles by Montalban, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nos, C.
Right arrow Articles by Montalban, X.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis

Carlos Nos

Unitat de Neuroimmunologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain

Jaume Sastre-Garriga

Unitat de Neuroimmunologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain

Cecília Borrlàs

Unitat de Neuroimmunologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain

Jordi Río

Unitat de Neuroimmunologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain

Mar Tintoré

Unitat de Neuroimmunologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain

Xavier Montalban

Unitat de Neuroimmunologia Clínica, Hospital Vall d'Hebron, Barcelona, Spain, xavier.montalban{at}unic-em.com

Background: Intravenous methylprednisolone (IVMP) has been shown to hasten recovery from attacks of multiple sclerosis (MS) without altering the long term evolution of the condition; however, there is little evidence available to suggest which patients are more likely to benefit from IVMP treatment. Objective: To measure clinical change after IVMP treatment and to identify predictors of good outcome. Methods: Retrospective open-label study of medical records from 51 patients with clinically isolated syndromes or relapsing-remitting MS treated with IVMP for an acute attack (54 attacks). Results: A measurable neurological improvement was observed at one month in 44% of these attacks; the only predictor of Expanded Disability Status Scale (EDSS) change at one month was the severity of the attack. Conclusion: Attack severity predicts good response to IVMP when measured by means of EDSS.

Key Words: 6-methylprednisolone • clinically isolated syndrome • Expanded Disability Status Scale • multiple sclerosis • relapsing-remitting

Multiple Sclerosis, Vol. 10, No. 4, 413-416 (2004)
DOI: 10.1191/1352458504ms1068oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement